Methods for improving the immunogenicity and efficacy of cancer vaccines

Lorenzo Pilla, Soldano Ferrone, Cristina Maccalli

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: Cancer vaccines represent one of the oldest immunotherapy strategies. A variety of tumor-associated antigens have been exploited to investigate their immunogenicity as well as multiple strategies for vaccine administration. These efforts have led to the development of several clinical trials in tumors with different histological origins to test the clinical efficacy of cancer vaccines. However, suboptimal clinical results have been reported mainly due to the lack of optimized strategies to induce strong and sustained systemic tumor antigen-specific immune responses. Areas covered: We provide an overview of different types of cancer vaccines that have been developed and used in the context of clinical studies. Moreover, we review different preclinical and clinical strategies pursued to enhance the immunogenicity, stability, and targeting at tumor site of cancer vaccines. Expert opinion: Additional and appropriate preclinical studies are warranted to optimize the immunogenicity and delivery of cancer vaccines. The appropriate choice of target antigens is challenging; however, the exploitation of neoantigens generated from somatic mutations of tumor cells represents a promising approach to target highly immunogenic tumor-specific antigens. Remarkably, the investigation of the combination of cancer vaccines with immunomodulating agents able to skew the tumor microenvironment from immunosuppressive to immunostimulating will dramatically improve their clinical efficacy.

Original languageEnglish
Pages (from-to)765-784
Number of pages20
JournalExpert Opinion on Biological Therapy
Volume18
Issue number7
DOIs
Publication statusPublished - 3 Jul 2018

Fingerprint

Cancer Vaccines
Tumors
Neoplasm Antigens
Antigens
Combined Vaccines
Neoplasms
Tumor Microenvironment
Expert Testimony
Immunosuppressive Agents
Immunotherapy
Vaccines
Cells
Clinical Trials
Mutation

Keywords

  • Cancer vaccines
  • combination studies
  • immunogenicity
  • immunomodulating agents
  • neoantigens
  • tumor-associated antigens

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Methods for improving the immunogenicity and efficacy of cancer vaccines. / Pilla, Lorenzo; Ferrone, Soldano; Maccalli, Cristina.

In: Expert Opinion on Biological Therapy, Vol. 18, No. 7, 03.07.2018, p. 765-784.

Research output: Contribution to journalReview article

@article{de759fce709946f4b7e0cfc083818344,
title = "Methods for improving the immunogenicity and efficacy of cancer vaccines",
abstract = "Introduction: Cancer vaccines represent one of the oldest immunotherapy strategies. A variety of tumor-associated antigens have been exploited to investigate their immunogenicity as well as multiple strategies for vaccine administration. These efforts have led to the development of several clinical trials in tumors with different histological origins to test the clinical efficacy of cancer vaccines. However, suboptimal clinical results have been reported mainly due to the lack of optimized strategies to induce strong and sustained systemic tumor antigen-specific immune responses. Areas covered: We provide an overview of different types of cancer vaccines that have been developed and used in the context of clinical studies. Moreover, we review different preclinical and clinical strategies pursued to enhance the immunogenicity, stability, and targeting at tumor site of cancer vaccines. Expert opinion: Additional and appropriate preclinical studies are warranted to optimize the immunogenicity and delivery of cancer vaccines. The appropriate choice of target antigens is challenging; however, the exploitation of neoantigens generated from somatic mutations of tumor cells represents a promising approach to target highly immunogenic tumor-specific antigens. Remarkably, the investigation of the combination of cancer vaccines with immunomodulating agents able to skew the tumor microenvironment from immunosuppressive to immunostimulating will dramatically improve their clinical efficacy.",
keywords = "Cancer vaccines, combination studies, immunogenicity, immunomodulating agents, neoantigens, tumor-associated antigens",
author = "Lorenzo Pilla and Soldano Ferrone and Cristina Maccalli",
year = "2018",
month = "7",
day = "3",
doi = "10.1080/14712598.2018.1485649",
language = "English",
volume = "18",
pages = "765--784",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Methods for improving the immunogenicity and efficacy of cancer vaccines

AU - Pilla, Lorenzo

AU - Ferrone, Soldano

AU - Maccalli, Cristina

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Introduction: Cancer vaccines represent one of the oldest immunotherapy strategies. A variety of tumor-associated antigens have been exploited to investigate their immunogenicity as well as multiple strategies for vaccine administration. These efforts have led to the development of several clinical trials in tumors with different histological origins to test the clinical efficacy of cancer vaccines. However, suboptimal clinical results have been reported mainly due to the lack of optimized strategies to induce strong and sustained systemic tumor antigen-specific immune responses. Areas covered: We provide an overview of different types of cancer vaccines that have been developed and used in the context of clinical studies. Moreover, we review different preclinical and clinical strategies pursued to enhance the immunogenicity, stability, and targeting at tumor site of cancer vaccines. Expert opinion: Additional and appropriate preclinical studies are warranted to optimize the immunogenicity and delivery of cancer vaccines. The appropriate choice of target antigens is challenging; however, the exploitation of neoantigens generated from somatic mutations of tumor cells represents a promising approach to target highly immunogenic tumor-specific antigens. Remarkably, the investigation of the combination of cancer vaccines with immunomodulating agents able to skew the tumor microenvironment from immunosuppressive to immunostimulating will dramatically improve their clinical efficacy.

AB - Introduction: Cancer vaccines represent one of the oldest immunotherapy strategies. A variety of tumor-associated antigens have been exploited to investigate their immunogenicity as well as multiple strategies for vaccine administration. These efforts have led to the development of several clinical trials in tumors with different histological origins to test the clinical efficacy of cancer vaccines. However, suboptimal clinical results have been reported mainly due to the lack of optimized strategies to induce strong and sustained systemic tumor antigen-specific immune responses. Areas covered: We provide an overview of different types of cancer vaccines that have been developed and used in the context of clinical studies. Moreover, we review different preclinical and clinical strategies pursued to enhance the immunogenicity, stability, and targeting at tumor site of cancer vaccines. Expert opinion: Additional and appropriate preclinical studies are warranted to optimize the immunogenicity and delivery of cancer vaccines. The appropriate choice of target antigens is challenging; however, the exploitation of neoantigens generated from somatic mutations of tumor cells represents a promising approach to target highly immunogenic tumor-specific antigens. Remarkably, the investigation of the combination of cancer vaccines with immunomodulating agents able to skew the tumor microenvironment from immunosuppressive to immunostimulating will dramatically improve their clinical efficacy.

KW - Cancer vaccines

KW - combination studies

KW - immunogenicity

KW - immunomodulating agents

KW - neoantigens

KW - tumor-associated antigens

UR - http://www.scopus.com/inward/record.url?scp=85049885260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049885260&partnerID=8YFLogxK

U2 - 10.1080/14712598.2018.1485649

DO - 10.1080/14712598.2018.1485649

M3 - Review article

C2 - 29874943

AN - SCOPUS:85049885260

VL - 18

SP - 765

EP - 784

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 7

ER -